The information contained in this section should be read in conjunction with Johnson & Johnson's other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports … You can search for filings below. Listen to webcast. Further, Johnson & Johnson shares are down just 9.8% from their highs, while the S&P 500 is still down 18.6% from its 2020 high. Johnson & Johnson Reports 2020 Fourth-Quarter And Full Year Results - 2020 Fourth-Quarter Sales of $22.5 Billion reflecting growth of 8.3%, operational growth of 7.1%* and … ... uncertainties and other factors can be found in the company's most recently filed Annual Report on Form 10-K and Quarterly Report … Johnson & Johnson (JNJ) came out with quarterly earnings of $1.88 per share, beating the Zacks Consensus Estimate of $1.86 per share. Johnson & Johnson First Quarter Earnings Call and Webcast. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson … This compares to earnings of $1.97 per share a year … ... • Analysts expect Johnson & Johnson to report earnings of $1.86 per share and sales of $18.1 billion in the first quarter of … Earnings Presentation 3.1 MB. The company reports quarterly earnings on Tuesday. In order to read our … https://www.cnbc.com/2021/01/26/johnson-johnson-jnj-earnings-q4-2020.html Podcast 49 MB. Johnson & Johnson on Tuesday said it expected to report eagerly-awaited data on its COVID-19 vaccine early next week, and that it would be able to meet the delivery target for … ... Risk Factors," in the Company's most recently filed Quarterly Report on Form 10-Q and the … Johnson & Johnson Reports 2020 Fourth-Quarter And Full Year Results. SEC filings represent the financial reports and statements filed with the Securities and Exchange Commission by Johnson & Johnson. Johnson & Johnson on Tuesday reported third-quarter earnings and revenue that beat Wall Street's expectations, led by higher sales in its medical-device unit and higher …